tm logo
Trademark Search
BIOEPIS (COLOR)

View On IC.GC.CA

BIOEPIS (COLOR)
REGISTERED

on 22 Jul 2020

Last Applicant/ Owned by

SAMSUNG BIOEPIS CO. LTD.

107, Cheomdan-daero, Yeonsu-guIncheon

KR

Serial Number

1780404 filed on 02th May 2016

Registration Number

TMA1080678 registered on 22nd Jul 2020

Registration expiry Date

22nd Jul 2030

Correspondent Address

480-THE STATION, 601 WEST CORDOVA STREETVANCOUVER

BRITISH COLUMBIA

CA

V6B1G1

BIOEPIS (COLOR)

Vienna Information

29 . 1 . 1

Red, pink, orangeRouge, rose, orangé

29 . 1 . 3

GreenVert

29 . 1 . 5

VioletViolet

Trademark usage description

antibody formulation for treatment of immunologic deficiency syndromes and allergies, for immunoregulation, for treatment of autoimmune diseases, for Read More

Classification Information

Class [005]
Antibody formulation for treatment of immunologic deficiency syndromes and allergies, for immunoregulation, for treatment of autoimmune diseases, for treatment of inflammatory bowel diseases, inflammatory connective tissue diseases and injuries and asthma, for treatment of arthritis, for acting as anti-cancer agents, for treatment of cancer, for treatment of tumor, for treatment of central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease and Huntington's disease, and for treatment of diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; Protein formulations for treatment of immunologic deficiency syndromes and allergies, for immunoregulation, for treatment of autoimmune diseases, for treatment of inflammatory bowel diseases, inflammatory connective tissue diseases and injuries and asthma, for treatment of arthritis, for acting as anti-cancer agents, for treatment of cancer, for treatment of tumor, for treatment of central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease and Huntington's disease, and for treatment of diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes and allergies; Preparations for immunoregulation; Preparations for treatment of autoimmune diseases; Preparations for treatment of inflammatory diseases, namely, pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases and asthma and pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; Preparations for treatment of arthritis; Anti-cancer agents; Preparations for treatment of cancer; Preparations for treatment of tumors; Preparations for diagnosis, namely, preparations for diagnosis of immunologic deficiency syndromes and allergies, preparations for diagnosis of autoimmune diseases, preparations for diagnosis of inflammatory bowel diseases, inflammatory connective tissue diseases and injuries and asthma, preparations for diagnosis of arthritis, preparations for diagnosis of tumor, preparations for diagnosis of central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease and Huntington's disease, preparations for diagnosis of diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism and diagnostic reagents for medical diagnostic use; Preparations for treatment of central nervous system disorders, namely, pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, Huntington's disease and pharmaceutical preparations for the treatment of the diseases, disorders and infections of the central nervous system namely brain, movement, ocular motility and spinal cord diseases; Preparations for treatment of metabolic diseases, namely, pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia and pharmaceutical preparations for the treatment of metabolic disorders, namely bulimia nervosa, anorexia, obesity and hypothyroidism; Biological tissue cultures for medical purposes.

Classification kind code

11

Class [042]
Pharmaceutical research and development; Bacteriological research; Biological research; Biotechnology research; Biopharmaceutical research and development; Research and development for new products for others; Material testing; Chemistry services, namely, chemistry consultation; Chemical research and analysis; Biotechnology consultation; Pharmaceutical development using animal cells; Scientific technology research in the field of plant genetics; Laboratory equipment rental.

Classification kind code

11

Mark Details

Serial Number

1780404

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 23
on 16th Feb 2018		Default Removed
Submitted for opposition 12
on 16th Feb 2018		Extension of Time
Submitted for opposition 18
on 30th Jan 2018		Extension of Time Refused
Submitted for opposition 15
on 19th Jul 2017		Correspondence Created
Submitted for opposition 12
on 24th Jan 2017		Extension of Time
Submitted for opposition 22
on 14th Jul 2016		Search Recorded
Submitted for opposition 20
on 14th Jul 2016		Examiner's First Report
Submitted for opposition 31
on 04th May 2016		Formalized
Submitted for opposition 1
on 03rd May 2016		Created
Submitted for opposition 30
on 02th May 2016		Filed